
|Videos|January 19, 2023
IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC
The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.
Advertisement
Episodes in this series

Advertisement
Related to this article

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
3
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
4
TCR-Based Strategies and Tolerable Combinations Begin to Narrow the Outcome Gap in Uveal Melanoma
5

